Zydus Cadila gets USFDA final nod for Deferasirox Tablets for Oral Suspension
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets for Oral Suspension in the strengths of 125 mg, 250 mg and 500 mg.
Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus Cadila seeks DCGI approval for clinical trial of hepatitis drug PegiHep in COVID-19
